Onivyde with talazoparib or temozolomide for children with returned solid tumors and Ewing sarcoma
Tests Onivyde paired with talazoparib or temozolomide in young people with recurrent solid tumors.
Key facts
- Who runs it
- St. Jude Children's Research Hospital
- Where
- Atlanta, Aurora, Houston, Memphis, Minneapolis, Palo Alto, and Washington D.C., United StatesSee the 7 sitesAlso in 1 other country, 3 sites
- Trial code
- Registry title
- Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 90 people, planned
- Started
- 9 Jun 2021
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Onivyde
- Talazoparib
- Temozolomide
- Record updated
- 19 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults whose solid tumor has come back or never went away after treatment. Phase II is only for recurrent or refractory Ewing sarcoma.
- Age
- Older than 12 months and younger than 30 years.
- Sex
- All sexes can join.
- Disease stage
- Phase I: a solid tumor outside the brain and spinal cord that has come back or never went away, and cannot be cured by treatment. Phase II: Ewing sarcoma that has come back or never went away after first-line treatment. The disease must be measurable or evaluable.
- Earlier treatment
- Phase I: earlier treatment with irinotecan, temozolomide or a PARP inhibitor other than talazoparib is allowed. Phase II: first-line treatment must have been given. Patients must have recovered from the side effects of earlier treatment, with waiting times after chemotherapy, antibodies, radiation and growth factors.
- Biomarker or test result
- Phase II: Ewing sarcoma with an EWSR1-FLI1 translocation or other EWS rearrangement at first diagnosis. Expansion arm A2: a harmful change in a gene involved in DNA repair, found by earlier gene testing.
Main reasons for not taking part
- Pregnant or breastfeeding women
- People of reproductive age who do not agree to use two birth control methods
- Poor kidney, liver, lung or blood counts
- Not recovered from side effects of earlier treatment
- Performance score of 50% or lower on the Karnofsky or Lansky scale
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Patients must be > 12 months and < 30 years at the time of enrollment on study
- Phase I
- Patients with refractory or recurrent non-central nervous system (CNS) solid tumors not amenable to curative treatment are eligible. Patients must have had histologic verification of malignancy at original diagnosis or at the time of relapse. Patients eligible for the expansion cohort, A2, will include non-ES patients with refractory or recurrent non-CNS solid tumors with a deleterious alteration in germline or somatic genes involved in HR repair and DSBs signaling, germline or somatic assessed by prior comprehensive sequencing performed in a CLIA-approved (or equivalent) facility; Phase II
- Patients with refractory or recurrent Ewing sarcoma (during or after completion of first-line therapy). Refractory disease is defined as progression during first line treatment or within 12 weeks of completion of first line treatment. Recurrent disease includes patients who received first line treatment and experienced disease progression at any time point >12 weeks from the completion of first line therapy
- Patients must have a histologic diagnosis of Ewing sarcoma with EWSR1- FLI1 translocation or other EWS rearrangement at the time of initial diagnosis. Repeat biopsy at the time of disease recurrence is strongly encouraged but it is not required/mandated for enrollment; Disease status
- Patients must have either measurable or evaluable disease (see Section 7.0 for definitions). Measurable disease includes soft tissue disease evaluable by cross-sectional imaging (RECIST). Patients with bone disease without a measurable soft tissue component or bone marrow disease only are eligible for the phase 1 and phase 2 study but will not be included in the OR endpoint
- Performance level: Karnofsky > 50% for patients > 16 years of age and Lansky > 50% for patients < 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score; Prior therapy; Phase I Patients who have received prior therapy with an irinotecan-based or temozolomide-based regimen are eligible. Patients who have received prior therapy with a PARP inhibitor other than talazoparib are eligible; Phase II
- Patients should have received first line therapy and developed either refractory or recurrent disease (first relapse)
- Organ function: Must have adequate organ and bone marrow function as defined by the following parameters:
- Patients with solid tumors not metastatic to bone marrow:
- Peripheral absolute neutrophil count (ANC) >1,000/mm3 (1x109/L)
- Platelet count > 75,000/mm3 (75x109/L) (no transfusion within 7 days of enrollment)
- Hemoglobin > 9 g/dL (with or without support); In the phase I study, patients with solid tumors metastatic to bone marrow or with bone marrow hypocellularity defined as <30% cellularity in at least one bone marrow site will be eligible for study, but they will not be evaluable for hematologic toxicity. These patients must not be refractory to red cell or platelet transfusions. At least 2 of every cohort of 3 patients (in the phase I study) must be evaluable for hematologic toxicity. If dose limiting hematologic toxicity is observed at any dose level, all subsequent patients enrolled at that dose level must be evaluable for hematologic toxicity
- Adequate renal function defined as: Creatinine clearance or radioisotope GFR > 60ml/min/1.73m2 or a serum creatinine maximum based on age/sex: age 6months to <1 year, creatinine 0.4; 1 to < 2 years, creatinine 0.6; 2 < 6 years, creatinine 0.8; 6 < 10 years, creatinine 1; 10 to <13 years, creatinine 1.2; 13 to < 16 years creatinine 1.5 (males) or 1.4 (females); > 16 years, creatinine 1.7 (males) 1.4 (females)
- Adequate liver function defined as: normal liver function as defined by SGPT (ALT) concentration <5x the institutional ULN, a total bilirubin concentration <2x the institutional ULN for age, and serum albumin > 2g/dL
- Adequate pulmonary function defined as no evidence of dyspnea at rest and a pulse oximetry > 94% if there is a clinical indication for determination. Pulmonary function tests are not required
- Patients must have fully recovered from the acute toxic effects of chemotherapy, immunotherapy, surgery, or radiotherapy prior to entering this study:
- Myelosuppressive chemotherapy: Patient has not received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (8 weeks if received prior myeloablative therapy)
- Hematopoietic growth factors: At least 7 days must have elapsed since the completion of therapy with a growth factor. At least 14 days must have elapsed after receiving pegfilgrastim
- Biologic (anti-neoplastic agent): At least 7 days must have elapsed since completion of therapy with a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur
- Monoclonal antibodies: At least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody or 28 days have elapsed since last dose of the monoclonal antibody with complete resolution of symptoms related to treatment
- Radiotherapy: At least 2 weeks must have elapsed since any irradiation; at least 6 weeks must have elapsed since craniospinal RT, 131I-mIBG therapy or substantial bone marrow irradiation (e.g., >50% pelvis irradiation)
- Female participant who is post-menarchal must have a negative urine or serum pregnancy test and must be willing to have additional serum and urine pregnancy tests during the study
- Female or male participant of reproductive potential must agree to use effective contraceptive methods at screening and throughout duration of study treatment
Who cannot take part
- Pregnant or breast-feeding women will not be entered on this study. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use two methods of birth control: a medically accepted barrier of contraceptive method (e.g., male or female condom) and a second method of birth control during protocol therapy. Two highly effective methods of contraception are required for female patients during treatment and for at least 7 months after completing therapy. Male patients with female partners of reproductive potential and/or pregnant partners are advised to use two highly effective methods of contraception during treatment and for at least 4 months after the final dose
- Male and female participants must agree not to donate sperm or eggs, respectively, after the first dose of study drug through 105 days and 45 days after the last dose of study drug. Females considered not of childbearing potential include those who are surgically sterile (bilateral salpingectomy, bilateral oophorectomy, or hysterectomy)
- Pregnant or breastfeeding
Where in United States
Also in 1 other country, 3 sites
- Children's Healthcare of Atlanta/Emory University School of MedicineAtlanta, United StatesContact: Thomas Cash, MD, MScTaking people
- Children's Hospital ColoradoAurora, United StatesContact: Carrye Cost, MDTaking people
- Texas Children's Hospital/ Baylor College of MedicineHouston, United StatesContact: Sara Federico, MDNo longer taking part
- St. Jude Children's Research HospitalMemphis, United StatesContact: Sara M Federico, MDTaking people
- Children's Hospital and Clinics of MinnMinneapolis, United StatesContact: Kris Ann Schultz, MD (principal investigator)Taking people
- Lucille Packard Children's Hospital StanfordPalo Alto, United StatesContact: Allison Pribnow, MD, MPHTaking people
- Children's National Medical CenterWashington D.C., United StatesContact: AeRang Kim, PhDTaking people
About the trial
What the trial wants to find out
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and participants will be randomly assigned to either Arm A or Arm B. The purpose of the phase I study is to determine the highest tolerable doses of the combinations of treatment given in each Arm.
Read full original descriptionShow less
In Arm A, children and AYAs with recurrent or refractory solid tumors will receive 2 medications called Onivyde and talazoparib. Onivyde works by damaging the DNA of the cancer cell and talazoparib works by blocking the repair of the DNA once the cancer cell is damaged. By damaging the tumor DNA and blocking the repair, the cancer cells may die. In Arm B, children and AYAs with recurrent or refractory solid tumors will receive 2 medications called Onivyde and temozolomide. Both of these medications work by damaging the DNA of the cancer call which may cause the tumor(s) to die.
Once the highest doses are reached in Arm A and Arm B, then "expansion Arms" will open. An expansion arm treats more children and AYAs with recurrent or refractory solid tumors at the highest doses achieved in the phase I study. The goal of the expansion arms is to see if the tumors go away in children and AYAs with recurrent or refractory solid tumors. There will be 3 "expansion Arms". In Arm A1, children and AYAs with recurrent or refractory solid tumors (excluding Ewing sarcoma) will receive Onivyde and talazoparib. In Arm A2, children and AYAs with recurrent or refractory solid tumors, whose tumors have a problem with repairing DNA (identified by their doctor), will receive Onivyde and talazoparib. In Arm B1, children and AYAs with recurrent or refractory solid tumors (excluding Ewing sarcoma) will receive Onivyde and temozolomide.
Once the highest doses of medications used in Arm A and Arm B are determined, then a phase II study will open for children or young adults with Ewing sarcoma that has recurred or is refractory following treatment received after the initial diagnosis. The trial will test the same 2 combinations of therapy in Arm A and Arm B. In the phase II, a participant with Ewing sarcoma will be randomly assigned to receive the treatment given on either Arm A or Arm B.
The 2 groups in the trial
- (Arm A) ONI plus TALExisting treatment, for comparison
The phase I/II study will evaluate a treatment regimen; nanoliposomal irinotecan (nal-IRN, Onivyde) plus talazoparib (TAL)
Treatment: Onivyde and Talazoparib
- (Arm B) ONI plus TMZExisting treatment, for comparison
The phase I/II study will evaluate a treatment regimen; Onivyde (ONI) plus temozolomide (TMZ)
Treatment: Onivyde and Temozolomide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma
- Plain-language title
- Onivyde with talazoparib or temozolomide for children with returned solid tumors and Ewing sarcomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 19 May 2026